While chimeric antigen receptor T-cell therapies (CAR-T cells) can bind to any particular cancer cell surface antigen, engineered TCRs can only bind to MHC-presented peptides on the cancer cell surface (Figure 2D). Here, HLA-C is linked to cancer.